Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on or Are Intolerant to a PD 1/L 1, EGFR, or ALK Inhibitor
NCT Number:
NCT04681131
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lung
Study Objectives:
To assess antitumor activity of BA3011 alone and in combination with nivolumab.
To assess the safety of BA3011 alone and in combination with nivolumab.
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
Study Documents
(MUSC NetID required for document access)